{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:07Z","timestamp":1793656507781,"version":"4.5.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41409-026-02802-7","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:40:59Z","timestamp":1771051259000},"page":"492-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9372-9911","authenticated-orcid":false,"given":"Yu","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1424","authenticated-orcid":false,"given":"Kotaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-7909","authenticated-orcid":false,"given":"Ryo","family":"Hanajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-8088","authenticated-orcid":false,"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-3202","authenticated-orcid":false,"given":"Takahide","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-723X","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9918","authenticated-orcid":false,"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7339-9800","authenticated-orcid":false,"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2022009019.","journal-title":"Blood Adv"},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2020001900.","journal-title":"Blood Adv"},{"key":"2802_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349\u201358. https:\/\/doi.org\/10.1182\/blood.2021015209.","journal-title":"Blood"},{"key":"2802_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011489","author":"MD Jain","year":"2023","unstructured":"Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, et al. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR-T consortium. Blood Adv. 2023. https:\/\/doi.org\/10.1182\/bloodadvances.2023011489.","journal-title":"Blood Adv"},{"key":"2802_CR5","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2020001837.","journal-title":"Blood Adv"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1158\/2643-3230.Bcd-24-0052","volume":"5","author":"F Stella","year":"2024","unstructured":"Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, et al. A multicenter real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in large B-cell lymphomas. Blood Cancer Discov. 2024;5:318\u201330. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-24-0052.","journal-title":"Blood Cancer Discov"},{"key":"2802_CR7","first-page":"193","volume":"11","author":"Y Atsuta","year":"2022","unstructured":"Atsuta Y, Okamoto S, Teshima T. Establishment of a cellular therapy registry in Japan, a platform for data sharing for research, industry, and regulatory use. J Hematopoietic Cell Transplant. 2022;11:193\u20138.","journal-title":"J Hematopoietic Cell Transplant"},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/jco.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42:205\u201317. https:\/\/doi.org\/10.1200\/jco.23.01097.","journal-title":"J Clin Oncol"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143:496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243.","journal-title":"Blood"},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6.","journal-title":"Lancet"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02802-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02802-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:19:24Z","timestamp":1775571564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02802-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02802-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YY received honoraria from AbbVie, Genmab, Gilead Sciences, Bristol-Myers Squibb and Chugai Pharmaceutical. YK received honoraria from Chugai Pharmaceutical. HG received honoraria from Sanofi, Bristol-Myers Squibb, Gilead Sciences, Kyowa Kirin, and Symbio and research funding from Bristol-Myers Squibb, Novartis, Gilead Sciences, Chugai Pharmaceutical, Kyowa Kirin, Takeda, Meiji, and MSD. KM received honoraria from Janssen and Sanofi. TS received honoraria from AbbVie, Genmab, Chugai Pharmaceutical, Gilead Sciences, and Bristol-Myers Squibb and research funding from Novartis. SM received honoraria from Gilead Sciences and Bristol-Myers Squibb. MS received honoraria from AbbVie, Gilead Sciences, Bristol-Myers Squibb, Novartis, and Chugai Pharmaceutical. K Kataoka received honoraria from Ono Pharmaceutical, Eisai, Astellas Pharma, Novartis, Chugai Pharmaceutical, AstraZeneca, Sumitomo Pharma, Kyowa Kirin, Janssen Pharmaceutical, MSD, Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol Myers Squibb, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Alexion Pharmaceuticals, AbbVie, Meiji Seika Pharma, Sanofi, Sysmex, Mundipharma, Incyte Corporation, Kyorin Pharmaceutical, PharmaEssentia Japan, Gilead Sciences, Kowa, Amgen, Nippon Kayaku, Asahi Kasei Pharma, and The Chemo-Sero-Therapeutic Research Institute, received scholarship grant from Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, Shionogi, Daiichi Sankyo, Sumitomo Pharma, Chugai Pharmaceutical, Teijin Pharma, Japan Blood Products Organization, JCR Pharmaceuticals, and Nippon Kayaku, received research funding from Otsuka Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Chordia Therapeutics, Genmab, Bristol-Myers Squibb, Meiji Seika Pharma, Regeneron, and Janssen Pharmaceutical, and has a patent for Genetic alterations as a biomarker in T-cell lymphomas issued and licensed and a patent for PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy issued and licensed. K Kato received honoraria from AbbVie, Chugai, Gilead Sciences, and Novartis and research funding from AbbVie, Astellas, MSD, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, Ono, Gilead Sciences, and Nippon Shinyaku. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all participants. This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the ethics committees of the Japanese Society for Transplantation and Cellular Therapy (reference number: 24-7) and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (reference number: 2024-3237).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}